T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. - Wikidata - wikimedia - TriplyDB

T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.

T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.

http://www.wikidata.org/entity/Q37208738

about

Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy Association of Protein Translation and Extracellular Matrix Gene Sets with Breast Cancer Metastasis: Findings Uncovered on Analysis of Multiple Publicly Available Datasets Using Individual Patient Data Approach Immune DNA signature of T-cell infiltration in breast tumor exomes.CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors Pathway-based personalized analysis of breast cancer expression data.The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy.Enumerating the gene sets in breast cancer, a "direct" alternative to hierarchical clustering.Predicting prognosis of breast cancer with gene signatures: are we lost in a sea of data?Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures.Inhibition of Hematopoietic Cell Kinase Activity Suppresses Myeloid Cell-Mediated Colon Cancer Progression MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer.Distinctive responsiveness to stromal signaling accompanies histologic grade programming of cancer cells Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer.Preliminary characterization of IL32 in basal-like/triple negative compared to other types of breast cell lines and tissues.Lack of sufficiently strong informative features limits the potential of gene expression analysis as predictive tool for many clinical classification problems.Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures.Breast cancer patients' clinical outcome measures are associated with Src kinase family member expression.Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization Predicting response and survival in chemotherapy-treated triple-negative breast cancer.Immunoglobulin kappa C predicts overall survival in node-negative breast cancer.Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment.Impact of CD68/(CD3+CD20) ratio at the invasive front of primary tumors on distant metastasis development in breast cancer Dual roles for immune metagenes in breast cancer prognosis and therapy prediction.GOBO: gene expression-based outcome for breast cancer online An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer.Serum soluble CD14 is a potential prognostic indicator of recurrence of human breast invasive ductal carcinoma with Her2-enriched subtype.Modelling the spatial heterogeneity and molecular correlates of lymphocytic infiltration in triple-negative breast cancer.Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial.Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status.Combining functional genomics strategies identifies modular heterogeneity of breast cancer intrinsic subtypes Tumor Infiltrating Lymphocytes - The Next Step in Assessing Outcome and Response to Treatment in Patients with Breast Cancer Intratumoral CD8⁺ cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancer Kinome expression profiling and prognosis of basal breast cancers A pharmacogenomic method for individualized prediction of drug sensitivity Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy.Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.Breast cancer - one term, many entities?Profile of differentially expressed intratumoral cytokines to predict the immune-polarizing side effects of tamoxifen in breast cancer treatment A gene signature for predicting outcome in patients with basal-like breast cancer.

P2860

Q26745444-7981E431-3EBC-4249-9551-0A91216F1122 Q30000323-C2323F28-71D4-4C10-AFB4-8E11AFB973DC Q30377226-409360A0-00CA-4E52-B479-169B2982A551 Q30442426-3FE22A84-D2D0-4E25-A34E-683F3903D27D Q30949620-805F940D-4DCE-476F-B3A5-035603834469 Q33660069-0D817AAB-E983-4516-B7F7-7C3E59136DC3 Q33669571-636ABFB5-181F-4EFE-9334-CB83EE1E91AE Q33751916-7748BF21-B8C2-483B-A91F-AB06FA2119DA Q33769821-3DE843C7-3664-46B3-99E6-0E6BBE6119C0 Q33788520-E5D1B3A8-FC13-4170-87DF-B253CE54A4DB Q33821187-ABD0FF89-82AE-4916-AC78-4090D74E08DA Q33843799-842E2160-74F8-405D-958E-494DFF4FB3BE Q33916413-CA88241E-D1BE-4E7D-82D3-4F5EBDD7CA00 Q33916814-9F046122-3CFB-4E9F-9C31-B6BED01B79D2 Q34042748-9238089D-0CAD-4FEE-BFB8-FA98E37DF9D3 Q34088408-1680F12B-8DB6-4B2C-9215-2E0EF394B238 Q34119025-B2A9DD67-AF9D-4BEF-BF0E-F2E4BFBE8BF9 Q34253693-6680B383-8A85-41C4-9131-0A8CCD18538B Q34339847-ADB47C0C-3F7D-454F-81F7-D0C5E04424D4 Q34354538-1847620E-272B-4FAE-B41C-15592B132C9E Q34427347-C7755F87-8912-4BC4-8489-B8E1C8AB476F Q34502899-69FD31E1-255D-4126-B9C1-C38409369E81 Q34541239-5BF966D0-58F8-485D-AA49-0F28C4FB9548 Q34558758-69F4D991-F29C-4AF9-B364-8B8FBBF9919C Q34704073-8E547064-B6DC-42C8-B659-607B26B3F82F Q34989075-01E8FB18-4BAA-4C01-9855-BFBB686D2C10 Q35005593-FFB27430-548E-44D7-A58C-C77DB611F6B9 Q35009369-D0C6E367-F2C7-4C4F-86C5-6B1C3097AE13 Q35060987-C37DD0D3-2387-4386-9EAB-3D2B6A380E56 Q35124596-055C5B2C-941C-47F7-9E09-A022DF3795BA Q35149532-2BB726AD-6F97-47F0-8CEB-A5E2C9606557 Q35149726-AC47C69C-1552-4A2E-93EA-2652DE9D6830 Q35151735-DD893497-D404-4B12-9701-3E70098E03D9 Q35166659-D63B8074-012E-451D-8C09-551530D757E6 Q35176386-7C1E3E1B-DC19-4C3B-BAFA-62B5CB667068 Q35227810-CBBE1FFA-EDA0-4DEB-A7B2-58BAFC1478C0 Q35314135-002542E5-2D82-4040-A7BA-DF9D1B0CC015 Q35370118-51B42946-0E25-463D-8EE0-2FCB491C5B28 Q35402584-D45E1FAA-E165-439F-AE6C-7CC97D964A94 Q35675013-8F4CE37C-F5E3-468D-9DEC-83F5D00F7B98

P2860

T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.

http://www.wikidata.org/entity/Q37208738

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

T-cell metagene predicts a fav ...... HER2-positive breast cancers.

@en

T-cell metagene predicts a fav ...... HER2-positive breast cancers.

@nl

type

label

T-cell metagene predicts a fav ...... HER2-positive breast cancers.

@en

T-cell metagene predicts a fav ...... HER2-positive breast cancers.

@nl

prefLabel

T-cell metagene predicts a fav ...... HER2-positive breast cancers.

@en

T-cell metagene predicts a fav ...... HER2-positive breast cancers.

@nl

P1433

Q37208738-91BBC38D-9D34-4F58-B699-E836E4B86471

P1476

Q37208738-62C5BC3F-5202-4D63-82AB-7217B168D6A0

P2093

Q37208738-0E415825-3631-465D-9384-B6107C640C3A

Q37208738-146F0381-8B26-429C-8A46-377889C28027

Q37208738-17C9DB1E-93CD-4B21-8429-B5BE97EF0EFE

Q37208738-31633BE6-66DD-4B6D-A25F-271657528985

Q37208738-536B89F6-7EFB-48BD-81FE-1DCE1C28D604

Q37208738-77CC597B-8874-4587-A4FE-B201C706CA8F

Q37208738-82326C1D-7965-4D0B-A8F6-2218D14D5C61

Q37208738-95F3E478-D791-4BF3-804D-D879F24465CD

Q37208738-B63D70AE-B9B8-463E-ABB2-82E01FF8CEBC

Q37208738-E142B62E-B2F6-4C78-9FA2-8EE21B36FB26

P2860

Q37208738-0164809D-A9B7-4D3C-9E02-EA20D883FEDF

Q37208738-04E01454-DD9E-4383-8F25-28DEC5CDE5B6

Q37208738-08A8D511-F840-4446-8CB1-90C132CEFD03

Q37208738-0AB100DD-B826-4D6D-BE03-A2B59A747134

Q37208738-1749D64A-41FD-48AB-9CE4-BC6DE9FF48D2

Q37208738-28E1778D-020A-4FF5-BE31-45E56ADD9E73

Q37208738-2F1180D8-ECD6-487A-A7DD-1F93BD47D204

Q37208738-3015FD69-E7D9-4862-8053-BD4260A52251

Q37208738-369F4901-0BC5-458E-AA39-6B8A78A3040B

Q37208738-378E66E2-F14C-4C4A-9EDB-CB65702135BC

P2888

Q37208738-87886D56-D56F-4C53-ADAC-41E2195225BA

P304

Q37208738-204C0923-B799-4C0E-84D8-39ECBAD0EBDC

P31

Q37208738-1372FCD9-8F12-47A9-B7AA-9FD4CB3CE4DB

P356

Q37208738-33D2BC38-9552-4A98-8C7E-E023B06C7B54

P433

Q37208738-AC13A70D-1D01-4E48-AF5F-0D66CA2701E2

P478

Q37208738-FC78B2DF-CD50-45CF-9D62-E4C4594C622F

P50

Q37208738-FC4DD37D-CF00-4EF2-B0ED-4F1A6819EB52

P577

Q37208738-E06B4C2E-C8BE-412B-808B-7C0C044560D1

P5875

Q37208738-A782C85E-102D-4D66-B012-27F705704330

P6179

Q37208738-0BC2DFA4-52BC-470B-9371-943AD9513069

P698

Q37208738-317A5F4B-EB67-42EB-89B4-E99404D85606

P932

Q37208738-18BB9511-6E55-41C4-91BF-0E95BD7B5952

P356

P1433

Breast Cancer Research

P1476

T-cell metagene predicts a fav ...... d HER2-positive breast cancers

@en

P2093

Achim Rody

http://www.w3.org/2001/XMLSchema#string

Andre Ahr

http://www.w3.org/2001/XMLSchema#string

Christine Solbach

http://www.w3.org/2001/XMLSchema#string

Cornelia Liedtke

http://www.w3.org/2001/XMLSchema#string

Dirk Metzler

http://www.w3.org/2001/XMLSchema#string

Eugen Ruckhaeberle

http://www.w3.org/2001/XMLSchema#string

Knut Engels

http://www.w3.org/2001/XMLSchema#string

Laos Pusztai

http://www.w3.org/2001/XMLSchema#string

Lars Hanker

http://www.w3.org/2001/XMLSchema#string

Manfred Kaufmann

http://www.w3.org/2001/XMLSchema#string

P2860

Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer.

Bioconductor: open software development for computational biology and bioinformatics

A gene atlas of the mouse and human protein-encoding transcriptomes

Inflammation and cancer

Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts.

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Molecular portraits of human breast tumours

A better way for a cancer cell to die

affy--analysis of Affymetrix GeneChip data at the probe level

Genes that mediate breast cancer metastasis to lung

P2888

P304

R15

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/BCR2234

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-03-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24187493

http://www.w3.org/2001/XMLSchema#string

P6179

1035269256

http://www.w3.org/2001/XMLSchema#string

P698

19272155

http://www.w3.org/2001/XMLSchema#string

P932

2688939

http://www.w3.org/2001/XMLSchema#string